Literature DB >> 10194839

Killed whole bacterial cells, a mucosal delivery system for the induction of immunity in the respiratory tract and middle ear: an overview.

J M Kyd1, A W Cripps.   

Abstract

Infectious diseases remain a leading cause of morbidity and mortality worldwide with mucosal membranes being the most frequent portals of entry of pathogenic micro-organisms. This has prompted studies aimed at the development of vaccination protocols that would lead to an increased protection of mucosae through an understanding of the common mucosal immune system as an immune communication network between mucosal sites. Recent studies have suggested that preferential sub-networks exist within the system and these studies have exploited the gut-associated lymphoid tissue (GALT)-lung sub-network in the development of oral vaccine strategies for infections of the respiratory tract and middle ear. Mucosal immunization with whole formalin killed Pseudomonas aeruginosa (Pa), Branhamella catarrhalis, nontypable Haemophilus influenzae (NTHi) or Streptococcus pneumoniae (Spn) results in enhanced homologous bacterial clearance from the lung of immune animals challenged with live bacteria. These studies have been extended to the middle ear where similar results have been observed for NTHi and Spn. Mechanisms responsible for inducing enhanced bacterial clearance from the airways include opsonising antibody, antigen specific CD4+ T helper cells, cytokine responses and recruitment of activated polymophonuclear neutrophils. The mechanisms induced by immunization which stimulates the immune system to rapidly mobilise both innate and specific immune responses during infection are the subject of ongoing research.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10194839     DOI: 10.1016/s0264-410x(98)00441-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

Review 1.  Ribosomal immunotherapy for recurrent respiratory tract infections in children.

Authors:  Marie C Béné; Gilbert C Faure
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

2.  Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae.

Authors:  L Goetsch; A Gonzalez; H Plotnicky-Gilquin; J F Haeuw; J P Aubry; A Beck; J Y Bonnefoy; N Corvaïa
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

3.  Intranasal immunization enhances clearance of nontypeable Haemophilus influenzae and reduces stimulation of tumor necrosis factor alpha production in the murine model of otitis media.

Authors:  A Sabirov; S Kodama; T Hirano; M Suzuki; G Mogi
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

4.  Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine.

Authors:  Xinan Jiao; Takashi Hirano; Yingchun Hou; Xin-Xing Gu
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

5.  Longitudinal evaluation of CD4+ and CD8+ peripheral blood and mammary gland lymphocytes in cows experimentally inoculated with Staphylococcus aureus.

Authors:  A L Rivas; F W Quimby; O Coksaygan; L Olmstead; D H Lein
Journal:  Can J Vet Res       Date:  2000-10       Impact factor: 1.310

6.  Intranasal immunization with a colloid-formulated bacterial extract induces an acute inflammatory response in the lungs and elicits specific immune responses.

Authors:  A Rial; D Lens; L Betancor; H Benkiel; J S Silva; J A Chabalgoity
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

7.  The development of an AIDS mucosal vaccine.

Authors:  Xian Tang; Zhiwei Chen
Journal:  Viruses       Date:  2010-01-22       Impact factor: 5.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.